

	Corresponding	author(s)	: David	L. Rimm	, MD	, PhC
--	---------------	-----------	---------	---------	------	-------

Last updated by author(s): Feb 15, 2019

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, seeAuthors & Referees and theEditorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main toyt, or Mathade section

~ .				
St	ำลา	ŀις	ŤΙ	\sim

1016	an statistical analyses, commit that the following items are present in the figure legend, that elegend, main text, of interfocus section.
n/a	Confirmed
	\blacksquare The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	🗶 A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
×	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
'	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

For data collection, we used an open source software called QuPath. The software and its documentation can be found at https:// qupath.github.jo/

Data analysis

We used watershed cell detection to segment the cells in the image with the following settings: Detection image: Hematoxylin OD; Requested pixel size: 0.5 μm; Background radius: 8 μm; Median filter radius: 0 μm; sigma: 1.5 μm; Minimum cell area: 10 μm2; Maximum cell area: 400 µm2; Threshold: 0.1; Maximum background intensity: 2. In order to classify detected cells into tumor cells, immune cells (TILs), stromal cells and others (false detections, background), we used neural network as a machine learning method with 8 hidden layers (maximum iterations: 100). The features used in the classification are listed below.

Nucleus: Area Nucleus: Perimeter Nucleus: Circularity Nucleus: Max caliper Nucleus: Min caliper Nucleus: Eccentricity

Nucleus: Hematoxylin OD mean Nucleus: Hematoxylin OD sum Nucleus: Hematoxylin OD std dev Nucleus: Hematoxylin OD max Nucleus: Hematoxylin OD min Nucleus: Hematoxylin OD range Nucleus: Eosin OD mean Nucleus: Eosin OD sum Nucleus: Eosin OD std dev

Nucleus: Eosin OD max

Nucleus: Eosin OD min Nucleus: Eosin OD range Cell: Area Cell: Perimeter Cell: Circularity Cell: Max caliper Cell: Min caliper Cell: Eccentricity Cell: Eosin OD mean Cell: Eosin OD std dev Cell: Eosin OD max Cell: Eosin OD min Cytoplasm: Eosin OD mean Cytoplasm: Eosin OD std dev Cytoplasm: Eosin OD max Cytoplasm: Eosin OD min Nucleus/Cell area ratio Smoothed: 25 µm: Nucleus: Area Smoothed: 25 µm: Nucleus: Perimeter Smoothed: 25 µm: Nucleus: Circularity Smoothed: 25 µm: Nucleus: Max caliper Smoothed: 25 µm: Nucleus: Min caliper Smoothed: 25 µm: Nucleus: Eccentricity Smoothed: 25 µm: Nucleus: Hematoxylin OD mean Smoothed: 25 µm: Nucleus: Hematoxylin OD sum Smoothed: 25 µm: Nucleus: Hematoxylin OD std dev Smoothed: 25 µm: Nucleus: Hematoxylin OD max Smoothed: 25 µm: Nucleus: Hematoxylin OD min Smoothed: 25 µm: Nucleus: Hematoxylin OD range Smoothed: 25 µm: Nucleus: Eosin OD mean Smoothed: 25 µm: Nucleus: Eosin OD sum Smoothed: 25 µm: Nucleus: Eosin OD std dev Smoothed: 25 µm: Nucleus: Eosin OD max Smoothed: 25 µm: Nucleus: Eosin OD min Smoothed: 25 µm: Nucleus: Eosin OD range Smoothed: 25 µm: Cell: Area Smoothed: 25 µm: Cell: Perimeter Smoothed: 25 µm: Cell: Circularity Smoothed: 25 µm: Cell: Max caliper Smoothed: 25 µm: Cell: Min caliper Smoothed: 25 µm: Cell: Eccentricity Smoothed: 25 µm: Cell: Eosin OD mean Smoothed: 25 µm: Cell: Eosin OD std dev Smoothed: 25 µm: Cell: Eosin OD max Smoothed: 25 µm: Cell: Eosin OD min Smoothed: 25 µm: Cytoplasm: Eosin OD mean Smoothed: 25 µm: Cytoplasm: Eosin OD std dev Smoothed: 25 µm: Cytoplasm: Eosin OD max Smoothed: 25 µm: Cytoplasm: Eosin OD min Smoothed: 25 µm: Nucleus/Cell area ratio Smoothed: 25 μm : Nearby detection counts Smoothed: 50 µm: Nucleus: Area Smoothed: 50 µm: Nucleus: Perimeter Smoothed: 50 µm: Nucleus: Circularity Smoothed: 50 µm: Nucleus: Max caliper Smoothed: 50 µm: Nucleus: Min caliper Smoothed: 50 µm: Nucleus: Eccentricity Smoothed: 50 µm: Nucleus: Hematoxylin OD mean Smoothed: 50 µm: Nucleus: Hematoxylin OD sum Smoothed: 50 μm : Nucleus: Hematoxylin OD std dev Smoothed: 50 µm: Nucleus: Hematoxylin OD max Smoothed: 50 µm: Nucleus: Hematoxylin OD min Smoothed: 50 µm: Nucleus: Hematoxylin OD range Smoothed: 50 µm: Nucleus: Eosin OD mean Smoothed: 50 µm: Nucleus: Eosin OD sum Smoothed: 50 µm: Nucleus: Eosin OD std dev Smoothed: 50 µm: Nucleus: Eosin OD max

Smoothed: 50 µm: Nucleus: Eosin OD min

Smoothed: 50 µm: Nucleus: Eosin OD range Smoothed: 50 µm: Cell: Area Smoothed: 50 µm: Cell: Perimeter Smoothed: 50 µm: Cell: Circularity Smoothed: 50 µm: Cell: Max caliper Smoothed: 50 µm: Cell: Min caliper Smoothed: 50 µm: Cell: Eccentricity Smoothed: 50 um: Cell: Fosin OD mean Smoothed: 50 µm: Cell: Eosin OD std dev Smoothed: 50 µm: Cell: Eosin OD max Smoothed: 50 µm: Cell: Eosin OD min Smoothed: 50 um: Cytoplasm: Eosin OD mean Smoothed: 50 µm: Cytoplasm: Eosin OD std dev Smoothed: 50 µm: Cytoplasm: Eosin OD max Smoothed: 50 µm: Cytoplasm: Eosin OD min Smoothed: 50 µm: Nucleus/Cell area ratio Smoothed: 50 um: Nearby detection counts

In order to help the algorithm perform an accurate classification, we also added smoothed object features at $25 \, \mu m$ and $50 \, \mu m$ radius to supplement the existing measurements of individual cells. Our algorithm (NN192) is available upon request and will be publicly available after publication.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Provide your data availability statement here.

Field-specific reporting

Please select the one below	\prime that is the best fit for your research. If	f you are not sure, read the appropriate sections before making your selection.
x Life sciences	Behavioural & social sciences	Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

Describe how sample size was determined, detailing any statistical methods used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

Data exclusions

Describe any data exclusions. If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Replication

Describe the measures taken to verify the reproducibility of the experimental findings. If all attempts at replication were successful, confirm this OR if there are any findings that were not replicated or cannot be reproduced, note this and describe why.

Randomization

Describe how samples/organisms/participants were allocated into experimental groups. If allocation was not random, describe how covariates were controlled OR if this is not relevant to your study, explain why.

Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental s	systems Methods			
n/a Involved in the study	n/a Involved in the study			
X Antibodies	ChIP-seq			
x Eukaryotic cell lines	Eukaryotic cell lines			
▼ Palaeontology	MRI-based neuroimaging			
Animals and other organism	ms '			
Human research participants				
Clinical data				
Policy information about <u>clinical s</u> All manuscripts should comply with th	studies ne ICMJE <u>guidelines for publication of clinical research</u> and a completed <u>CONSORT checklist</u> must be included with all submissions.			
Clinical trial registration	inical trial registration Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.			
Study protocol Note where the full trial protocol can be accessed OR if not available, explain why.				
Data collection Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.				

Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

Outcomes